Germany-based Boehringer Ingelheim has launched its corporate venture capital fund.
The Boehringer Ingelheim Venture Fund (BIVF) aims to invest, on a worldwide basis, in biotech and start-up companies that provide innovative therapeutic approaches and technologies to help drive innovation in medical science.
These may include new therapeutic concepts including stem cells and RNA silencing as well as new generation vaccines, new generation protein or antibody technologies, new molecular targets and first-in-class lead compounds.
Disease-related biomarkers would be an additional area of focus.
Boehringer Ingelheim has initially committed to investing a total fund volume of €100m with the first operations being made in 2010.
FinSMEs
31/03/2010